Clinical Trial Update: Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and efficacy of INGAP-Peptide in adults with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INGAP-Peptide (INGAP peptide)

Snippet

Sponsor: Exsulin Corporation | Conditions: Diabetes Mellitus, Non-Insulin-Dependent | Phase 2 | Status: COMPLETED